DERMATOLOGY SAUDI BOARD PROGRAM

Saudi Board Part Two Final Written Examination of Dermatology 2017

Objectives:

- Determine the quantity and quality of specialty knowledge base ranked as competent, so that the individual can be used as a referral source for the specialty.
- Using theoretical data, determine the candidate’s ability to think logically, to solve problems, to apply basic medical science to clinical problems, and to make judgments with valid comparisons.
- Screen candidates for the purposes of being allowed to take the final clinical examination.

Eligibility:

- Successful completion of the required period of residency training.
- Obtaining a training completion certificate (or equivalent) issued by the local supervisory committee based on a satisfactory Final In-Training Evaluation Report (FITER) and any other related requirements assigned by any mentioned scientific boards (e.g. research, publication, logbook, etc.). FITER example outlined in Appendix 6 in the exam rules and regulations document on SCFHS website.
- Any candidate missed a maximum of three (3) months of training of the whole residency program are allowed to sit for the exam (written and clinical), and his/her results will be suspended till that missing period is done.
- Registering for the examination at least one month before the exam date.

Rules:

- The Saudi Board Part II specialty written examination will be held once each year on a date published on the SCFHS website.
- Examination dates should be provided by the SEC in accordance with the fixed annual schedule submitted by the examination department.
- There shall be no resit examination.
• A candidate would remain eligible for Saudi Board Part II written examination for a period not longer than three years provided they could prove they had been clinically active.

• If the candidate did not pass within the three years, an exceptional attempt may be granted upon the approval of the scientific council, provided evidence of continuing clinical practice is presented.

• A candidate who failed to pass Saudi Board Part II written examination including the exceptional attempt has to repeat the final year of training, after which he/she is allowed to sit the Part II written examination twice after approval by the scientific council.

• After exhausting all the above attempts (maximum 6 attempts) the candidate will not be permitted to sit the Saudi Board Part II written examination.

**Examination Format:**

• A Saudi Board Part II specialty written examination shall consist of 210 SBA MCQs (majority shall consist of clinical scenarios). They will be divided into two papers, One will contain 100 Qs and the other one will contain 110 Qs. 200 Qs will be in dermatology and 10 Qs in Research, Ethics, Professionalism and Patient Safety. Ten unscored items can be added for pretesting purposes.

• The examination shall contain mostly type K2 questions (interpretation, analysis, reasoning and decision making) and type K1 questions (recall and comprehension).

• Clinical presentation questions include history, clinical finding and patient approach. Diagnosis and investigation questions; includes the possible diagnosis and diagnostic methodologies (laboratory investigation, radiological imaging and clinical procedures), Management questions; includes treatment and clinical management non-therapeutic, therapeutic, patient safety, complication. Health maintenance questions; includes health promotion, disease prevention, risk factors assessment, and prognosis, see examples below.

• The examination shall include basic concept and clinical questions relevant to Dermatology, see blueprint below.

**Examination Conduct and Duration:**

Exam period shall be two hours for a 100 question paper, and two hours and 15 minutes (135 minutes) for 110 questions paper. The exam will be delivered as a computer based test when available, otherwise paper and pencil.
Passing Score:

- The passing score is 70%. However, if the percentage of candidates passing the examination is less than 70%, the passing score can be lowered by one mark at a time aiming at achieving 70% passing rate or 65% passing score whichever comes first. Under no circumstances can the passing score be reduced below 65%.

- Alternatively, to set the passing score a standard setting method that is supported by published scientific evidence can be used, for which the Angoff method is recommended. The process to arrive to the passing score requires prior review and approval. If standard setting is used the above passing score regulation does not apply. See appendix 7 for more details in the exam rules and regulations document on the SCFHS website.

- To set a passing score using a standard setting method (b), the specialty examination committee must obtain approval of the process and passing score from the SCFHS Assistant General Secretary for Postgraduate Studies one month prior to exam administration.

Declaration of Result:

All score reports shall go through a post-hoc item analysis before being issued and approved by the SCFHS and SEC within two weeks of the examination.

Exemption:

SCFHS at present has no reciprocal arrangement with respect to this examination or qualification by any other college or board, in any specialty.
Suggested References for Saudi Board Part II Final Written Examination of Dermatology

Textbooks:

1. Rook’s Text Book of Dermatology, 9th edition
2. Fitzpatrick’s Dermatology in General Medicine, 9th edition
4. Lever’s Histopathology of Skin, 11th edition
5. Weedon's Skin Pathology, 4th edition
7. Treatment of Skin Diseases by Mark Lebwohl, 4th edition
8. Dermatologic Surgery: Requisites in Dermatology by Allison T. Vidimos, Christie T.
10. Pediatric Dermatology: Requisites in Dermatology by Howard B. Pride MD, Albert C. Yan, and Andrea L. Zaenglein
11. Neonatal Dermatology by Lawrence F. Eichenfield MD, Ilona J. Frieden MD, and Nancy B. Esterly MD

Journals

1. JAMA Dermatology
2. British journal of Dermatology
3. Journal of the American Academy of Dermatology
4. International Journal of Dermatology
5. Pediatric dermatology
6. Dermatological therapy
7. UpToDate
8. Others journals related to dermatology
## MCQ Test Blueprint for Dermatology Board exam Part II

<table>
<thead>
<tr>
<th>No</th>
<th>Section</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Basic science</td>
<td>10-20</td>
</tr>
<tr>
<td>2</td>
<td>Papulosqamous dermatosis and others&lt;sup&gt;1&lt;/sup&gt;</td>
<td>15-25</td>
</tr>
<tr>
<td>3</td>
<td>Urticaria, Erythemas, purpura and others&lt;sup&gt;2&lt;/sup&gt;</td>
<td>15-25</td>
</tr>
<tr>
<td>4</td>
<td>Adnexal diseases and others&lt;sup&gt;3&lt;/sup&gt;</td>
<td>15-25</td>
</tr>
<tr>
<td>5</td>
<td>Connective tissue, Metabolic and systemic diseases</td>
<td>15-25</td>
</tr>
<tr>
<td>6</td>
<td>Vesiculobullous diseases</td>
<td>10-15</td>
</tr>
<tr>
<td>7</td>
<td>Infections, infestations and bites</td>
<td>15-25</td>
</tr>
<tr>
<td>8</td>
<td>Genodermatosis</td>
<td>10-20</td>
</tr>
<tr>
<td>9</td>
<td>Disorder due to physical agents</td>
<td>1-10</td>
</tr>
<tr>
<td>10</td>
<td>Neoplasm of the skin</td>
<td>20-30</td>
</tr>
<tr>
<td>11</td>
<td>Dermatotherapy and dermatologic surgery</td>
<td>30-40</td>
</tr>
<tr>
<td>12</td>
<td>Research, Ethics, Professionalism and Patient Safety</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td><strong>210</strong></td>
</tr>
</tbody>
</table>

<sup>1</sup> Others include: **lichenoid and eczematous disorders**

<sup>2</sup> Others include: **vascular disease and granuloma**

<sup>3</sup> Others include: **hair, nail, mucous membrane and pigment disorders**
Example Questions

EXAMPLES OF K2 QUESTIONS:

An 18 year-old man presents to the Dermatology Clinic with a non-tender penile erosion that has been present for two weeks. An indurated border and non-tender bilateral inguinal lymphadenopathy are also confirmed.

What is the most likely diagnosis?

A. HIV  
B. Chancroid  
C. Herpes simplex  
D. Primary syphilis

EXAMPLES OF K1:

Which of the following causes oral hairy leukoplakia?

A. Cytomegalovirus  
B. Epstein-Barr virus  
C. Varicella zoster virus  
D. Herpes simplex virus type 1